Avadel Pharmaceuticals (AVDL)

• Market cap: $721M
• 1 day: -0.67%
• 5 days: -8.58%
• 1 month: -1.19%
• 3 months: -32.18%
• 6 months: -42.88%
• Year to date: -32.18%
• 1 year: -54.54%
• 5 years: 2.90%
• 10 years: -60.19%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Employees: 188

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

104% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $12.9M

70% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 40

4.8% more ownership

Funds ownership: 77.44% [Q3] → 82.24% (+4.8%) [Q4]

10% less funds holding

Funds holding: 175 [Q3] → 157 (-18) [Q4]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]

15% less capital invested

Capital invested by funds: $978M [Q3] → $833M (-$145M) [Q4]

43% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 40

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 61% upside
• Avg. target: $15.80 112% upside
• High target: $21 182% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 26% 1-year accuracy 44 / 171 met price target	155% upside $19	Buy Reiterated	4 Mar 2025
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 13 / 26 met price target	182% upside $21	Buy Reiterated	4 Mar 2025
Deutsche Bank David Hoang 35% 1-year accuracy 6 / 17 met price target	61% upside $12	Buy Initiated	11 Feb 2025
UBS Ashwani Verma 17% 1-year accuracy 3 / 18 met price target	88% upside $14	Buy Maintained	13 Jan 2025
Piper Sandler David Amsellem 47% 1-year accuracy 15 / 32 met price target	74% upside $13	Overweight Maintained	10 Jan 2025